TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35546275

Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide-1 receptor agonist
Number of subjects: 10675

Group type: COMPARATOR
Intervention: Sulphonylureas, thiazolidinediones, meglitinides or insulin
Number of subjects: 10675
Study: 35546396

Group type: EXPERIMENTAL
Intervention: Manual therapy and stabilization occlusal splint
Number of subjects: 35
Study: 35546401

Group type: EXPERIMENTAL
Intervention: Pronolis®HD mono 2.5% (high-density sterile viscoelastic solution of hyaluronic acid)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Pronolis®HD mono 2.5%
Number of subjects: 166
Study: 35546402

Group type: EXPERIMENTAL
Intervention: 4-hydroxysalicylanilide (HDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-hydroxysalicylanilide (HDS) in combination with melphalan and bortezomib
Number of subjects: 0
Study: 35546414

Group type: EXPERIMENTAL
Intervention: Ramosetron ODT 0.1 mg administered after discharge on postoperative days 1 and 2
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (metoclopramide 10 mg administered only when nausea/vomiting occurred)
Number of subjects: 138
Study: 35546525

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35546555

Group type: EXPERIMENTAL
Intervention: Anakinra (100-300 mg administered intravenously for 15 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (in the context of ongoing Phase IIB trial)
Number of subjects: 0
Study: 35546638

Group type: EXPERIMENTAL
Intervention: Penetrating keratoplasty (PKP)
Number of subjects: 316
Study: 35546669

Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m² initial dose)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 256
Study: 35546672

Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium bromide
Number of subjects: 5
Study: 35546790

Group type: EXPERIMENTAL
Intervention: Dulaglutide 3.0 mg
Number of subjects: 2958

Group type: EXPERIMENTAL
Intervention: Dulaglutide 4.5 mg
Number of subjects: 2958

Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 2958
Study: 35546953

Group type: EXPERIMENTAL
Intervention: My Grief app for 4 weeks
Number of subjects: 13
Study: 35547849

Group type: EXPERIMENTAL
Intervention: 100 mcg of mRNA-1273
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mcg of mRNA-1273.351
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalent vaccine of 25 mcg each of mRNA-1273 and mRNA-1273.351
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third mRNA vaccination
Number of subjects: 0
Study: 35547857

Group type: EXPERIMENTAL
Intervention: Pain training for respite workers (3-3.5 hours duration)
Number of subjects: 0
Study: 35548056

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 724

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 724
Study: 35548075

Group type: EXPERIMENTAL
Intervention: Digital exercise programme (Safe Step) with optional supportive strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital fall prevention intervention
Number of subjects: 0
Study: 35548436

Group type: EXPERIMENTAL
Intervention: Physiological control mode
Number of subjects: 6
Study: 35548439

Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 90
Study: 35548446

Group type: EXPERIMENTAL
Intervention: Reduced bolus bivalirudin (80% of normal dose)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Normal bolus bivalirudin
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Postoperative net adverse clinical events (NACEs)
Number of subjects: 204
Study: 35548564

Group type: EXPERIMENTAL
Intervention: Asian-based oil blends rich in unsaturated fats (refined rice bran, sesame, and flaxseed oils)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Refined olive oil
Number of subjects: 66
Study: 35548581

Group type: EXPERIMENTAL
Intervention: Dynamic Exercise Program (DEP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 35549377

Group type: EXPERIMENTAL
Intervention: Successful recanalization (Thrombolysis in Cerebral Infarction scale score ≥2b)
Number of subjects: 3057

Group type: EXPERIMENTAL
Intervention: NIHSS at 24 hours
Number of subjects: 3057

Group type: EXPERIMENTAL
Intervention: NIHSS at hospital discharge
Number of subjects: 3057
Study: 35549640

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35549674

Group type: EXPERIMENTAL
Intervention: Spartalizumab in combination with FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel)
Number of subjects: 67

Group type: COMPARATOR
Intervention: FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel)
Number of subjects: 67
Study: 35549733

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) control using the ARG algorithm
Number of subjects: 5

Group type: COMPARATOR
Intervention: Open-loop (OL) control
Number of subjects: 5
Study: 35549810

Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone (KRd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35549838

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35550037

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccines (various Emergency Use Authorization or licensed formulations)
Number of subjects: 265
Study: 35550158

Group type: EXPERIMENTAL
Intervention: Lower body temperature (Tb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower body temperature (Tb) during waking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma and CSF P-tau levels
Number of subjects: 0
Study: 35550708

Group type: EXPERIMENTAL
Intervention: Hormonal treatment (HT)
Number of subjects: 32
Study: 35550847

Group type: EXPERIMENTAL
Intervention: Ebola vaccine trial
Number of subjects: 0
Study: 35551049

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic period
Number of subjects: 166459
Study: 35551072

Group type: EXPERIMENTAL
Intervention: Surpass flow diverter treatment
Number of subjects: 38
Study: 35551077

Group type: EXPERIMENTAL
Intervention: Chest pain radiating to both arms
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Exertional chest pain during the last week
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Pain during activity
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Pain dependent on position, respiration or palpation (Men)
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Exertional chest pain during the last week (<70 years)
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Pain radiating to the left arm (<70 years)
Number of subjects: 1506
Study: 35551083

Group type: EXPERIMENTAL
Intervention: Computerised Dynamic Posturography (Equitest, NeuroCom, Clackamas, OR)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative posturographic results
Number of subjects: 45
Study: 35551087

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) on days 5-7, in addition to standard of care radiotherapy and immunotherapy.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care radiotherapy and immunotherapy.
Number of subjects: 60
Study: 35551122

Group type: EXPERIMENTAL
Intervention: ER2 recommendations in addition to usual ED care
Number of subjects: 356

Group type: COMPARATOR
Intervention: Usual ED care
Number of subjects: 356
Study: 35551148

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 14

Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of Macintosh to Airtraq
Number of subjects: 14
Study: 35551157

Group type: EXPERIMENTAL
Intervention: Work2Prevent intervention (4-session employment and HIV prevention intervention)
Number of subjects: 87
Study: 35551366

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccines (mRNA-1273, BNT162b2)
Number of subjects: 375
Study: 35551444

Group type: EXPERIMENTAL
Intervention: Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery
Number of subjects: 0
Study: 35551488

Group type: EXPERIMENTAL
Intervention: Plasma levels of Parkin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma levels of ATG5
Number of subjects: 0
Study: 35551610

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 24
Study: 35551866

Group type: EXPERIMENTAL
Intervention: Neuromodulation for pain
Number of subjects: 88
Study: 35551868

Group type: EXPERIMENTAL
Intervention: Neurostimulation-naïve patients
Number of subjects: 263

Group type: COMPARATOR
Intervention: Patients with previous SCS experience
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 263
Study: 35552391

Group type: EXPERIMENTAL
Intervention: FET-PET-based SIB intensity-modulated radiotherapy (78 Gy total dose, 2.6 Gy per fraction)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: FET-PET-based SIB intensity-modulated radiotherapy
Number of subjects: 17
Study: 35552447

Group type: EXPERIMENTAL
Intervention: Regorafenib, Hydroxychloroquine (HCQ), and Entinostat
Number of subjects: 20
Study: 35552504

Group type: EXPERIMENTAL
Intervention: Cardiovascular outpatient care visits in 2020
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiovascular hospitalizations in 2020
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiovascular mortality in 2020
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home deaths due to cardiovascular issues in 2020
Number of subjects: 0
Study: 35552677

Group type: EXPERIMENTAL
Intervention: Paclitaxel (PTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overexpression of SSR3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knockout (KO) of SSR3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRISPR knockout (KO) screen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation with survival in breast cancer patient cohorts treated with PTX
Number of subjects: 0
Study: 35552827

Group type: EXPERIMENTAL
Intervention: Tinzaparin (fixed dose, 10,000 Anti-Xa IU, OD)
Number of subjects: 291
Study: 35553047

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1600 mg
Number of subjects: 634

Group type: COMPARATOR
Intervention: Pregabalin 300 mg
Number of subjects: 634

Group type: COMPARATOR
Intervention: Ibuprofen 800 mg
Number of subjects: 634

Group type: COMPARATOR
Intervention: Ambulation during treatment
Number of subjects: 634

Group type: COMPARATOR
Intervention: Therapeutic ibuprofen 800 mg
Number of subjects: 634

Group type: COMPARATOR
Intervention: Paracetamol 2000 mg
Number of subjects: 634

Group type: COMPARATOR
Intervention: Ambulation or non-ambulation
Number of subjects: 634
Study: 35553414

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 54

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 54
Study: 35554583

Group type: EXPERIMENTAL
Intervention: Mild sleep-disordered breathing
Number of subjects: 912

Group type: COMPARATOR
Intervention: Obstructive sleep apnea
Number of subjects: 912
Study: 35554589

Group type: EXPERIMENTAL
Intervention: PAT HSAT
Number of subjects: 167

Group type: COMPARATOR
Intervention: PSG
Number of subjects: 167
Study: 35554653

Group type: EXPERIMENTAL
Intervention: MRI dedicated to the ED (after period)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Standard diagnostic workup without MRI (before period)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: MRI dedicated to the ED
Number of subjects: 380
Study: 35554877

Group type: EXPERIMENTAL
Intervention: Computer-assisted difficulty scoring system (CAD)
Number of subjects: 173
Study: 35557615

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (GC) exposure during pregnancy
Number of subjects: 80

Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 80
Study: 35558645

Group type: EXPERIMENTAL
Intervention: Opioid prescriptions at discharge
Number of subjects: 1345

Group type: COMPARATOR
Intervention: Trauma center volume
Number of subjects: 1345

Group type: COMPARATOR
Intervention: Alcohol and other drugs (AOD) status
Number of subjects: 1345
Study: 35559350

Group type: EXPERIMENTAL
Intervention: FGF23
Number of subjects: 62

Group type: COMPARATOR
Intervention: RAAS parameters (PRA-S, AngII, aldosterone)
Number of subjects: 62
Study: 35559387

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis combined with mechanical thrombectomy (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment and intravenous thrombolysis (Group B)
Number of subjects: 120
Study: 35559998

Group type: COMPARATOR
Intervention: sCD146 and Gal1 concentrations in women with normal pregnancies
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: sCD146 concentrations in women with preeclampsia
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Trophoblast migration
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: sCD146 as a biomarker
Number of subjects: 115
Study: 35560143

Group type: EXPERIMENTAL
Intervention: Genotyping with genome-wide SNP-arrays
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Glycome profiling
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: RNA sequencing
Number of subjects: 1100
Study: 35560860

Group type: EXPERIMENTAL
Intervention: Hispanic children
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black (NHB) children
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Hispanic and Non-Hispanic White (NHW) children
Number of subjects: 900

Group type: COMPARATOR
Intervention: MetS definitions
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: MetS prevalence
Number of subjects: 900
Study: 35561317

Group type: EXPERIMENTAL
Intervention: Long-term breast cancer survivors (10-15 years post-diagnosis)
Number of subjects: 6641

Group type: EXPERIMENTAL
Intervention: Breast cancer survivors with Charlson Comorbidity Index score ≥2
Number of subjects: 6641

Group type: COMPARATOR
Intervention: General population (cancer-free women matched by birth year and state)
Number of subjects: 6641
Study: 35561331

Group type: EXPERIMENTAL
Intervention: Conventional HCC (cHCC)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Elevated α-fetoprotein
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Multifocality
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: PRETEXT stage IV
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: cHCC vs FLC
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Unresectable tumors
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Disease-free status
Number of subjects: 262
Study: 35561554

Group type: EXPERIMENTAL
Intervention: T1 relaxometry measurement of periventricular gradient in early multiple sclerosis
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: T1 relaxometry measurement of periventricular gradient in progressive multiple sclerosis
Number of subjects: 191

Group type: COMPARATOR
Intervention: T1 relaxometry measurement in healthy controls
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: T1 relaxometry measurement
Number of subjects: 191
Study: 35562076

Group type: EXPERIMENTAL
Intervention: 400-m gait speed intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global cognition intervention (3MSE)
Number of subjects: 0
Study: 35562098

Group type: EXPERIMENTAL
Intervention: AI-assisted optical diagnosis
Number of subjects: 389
Study: 35562664

Group type: EXPERIMENTAL
Intervention: Non-technical skills (NTS) performance assessment using the modified Team Emergency Assessment Measure (TEAM) score
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Leadership in resuscitation situations
Number of subjects: 359
Study: 35562729

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NitroPOHL
Number of subjects: 24

Group type: COMPARATOR
Intervention: Baseline GBF
Number of subjects: 24
Study: 35562735

Group type: EXPERIMENTAL
Intervention: Targeted preventive program (TOF pilot2 study)
Number of subjects: 4633
Study: 35562737

Group type: EXPERIMENTAL
Intervention: Periodontitis group (PG)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Non-periodontitis group (NPG)
Number of subjects: 79
Study: 35562750

Group type: EXPERIMENTAL
Intervention: ctDNA-derived genomic markers
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: ctDNA fraction
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: blood-based tumor mutation burden (bTMB)
Number of subjects: 141
Study: 35562784

Group type: EXPERIMENTAL
Intervention: University of Jyvaskyla Active Aging Scale (UJACAS)
Number of subjects: 820
Study: 35562794

Group type: EXPERIMENTAL
Intervention: AX (Arachidonic Acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MCC (Microcrystalline Cellulose)
Number of subjects: 0
Study: 35565812

Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE) regimen for 4 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE) regimen
Number of subjects: 9
Study: 35566502

Group type: EXPERIMENTAL
Intervention: Submaximal cycle ergometer protocol (CPET)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Age, time since COVID-19, hospitalization, dizziness, joint pain, pre-existing cardiopulmonary disease, use of beta blockers
Number of subjects: 80
Study: 35566586

Group type: EXPERIMENTAL
Intervention: Severe OSA (AHI ≥30 events/h)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Moderate to severe OSA (AHI 15.0−29.9 and ≥30 events/h)
Number of subjects: 147

Group type: COMPARATOR
Intervention: No-OSA (AHI <5.0 events/h)
Number of subjects: 147
Study: 35567345

Group type: EXPERIMENTAL
Intervention: Higher dose of nusinersen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12 mg dose of nusinersen
Number of subjects: 0
Study: 35567422

Group type: EXPERIMENTAL
Intervention: Risdiplam, orally once daily for a median duration of 4.8 months (range, 0.3-9.2 months)
Number of subjects: 155
Study: 35567560

Group type: EXPERIMENTAL
Intervention: sLOX-1 levels in ACS patients
Number of subjects: 2924

Group type: EXPERIMENTAL
Intervention: sLOX-1 levels in ACS patients (T3)
Number of subjects: 2924

Group type: EXPERIMENTAL
Intervention: sLOX-1 levels in ACS patients undergoing serial intracoronary imaging and statin therapy
Number of subjects: 2924
Study: 35567559

Group type: EXPERIMENTAL
Intervention: Bone marrow activation (BM 18F-FDG uptake above the median maximal standardized uptake value)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Bone marrow activation
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Bone marrow activation and arterial 18F-FDG uptake
Number of subjects: 745
Study: 35567614

Group type: EXPERIMENTAL
Intervention: Speech features combined with demographics
Number of subjects: 103
Study: 35567655

Group type: EXPERIMENTAL
Intervention: TAPS scoring model (total score, 0-7 points) based on early brain injury indicators.
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Logistic regression model for predicting outcomes.
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Calibration of the prediction model.
Number of subjects: 825
Study: 35567671

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks (q4w)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Uptitration to approved dupilumab dose regimen (200 or 300 mg every 2 weeks)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 294
Study: 35567877

Group type: EXPERIMENTAL
Intervention: Intraoperative indocyanine green (ICG) test during LSG
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intraoperative indocyanine green (ICG) test
Number of subjects: 1
Study: 35567881

Group type: EXPERIMENTAL
Intervention: Machine learning (ML) analysis applied to 3D maxillofacial shapes
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: 3D geometric morphometrics combined with ML
Number of subjects: 280

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 280
Study: 35567913

Group type: EXPERIMENTAL
Intervention: BRAF V600E+ with BRCA1 or BRCA2 co-mutations (3 patients identified from MTB registry)
Number of subjects: 36966

Group type: EXPERIMENTAL
Intervention: BRAF V600E+ MSS patients
Number of subjects: 36966

Group type: EXPERIMENTAL
Intervention: BRAF V600E+ MSS patients with BRCA co-mutations
Number of subjects: 36966
Study: 35567914

Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (P+AI)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant (P+F)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: First-line palbociclib combinations
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Second- or later-line palbociclib combinations
Number of subjects: 170
Study: 35568047

Group type: EXPERIMENTAL
Intervention: Intranasal administration of bone marrow-derived allogeneic mesenchymal stromal cells (MSCs)
Number of subjects: 10
Study: 35568510

Group type: EXPERIMENTAL
Intervention: Single-shot popliteal sciatic nerve block
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Multivariable risk prediction model
Number of subjects: 1365
Study: 35568651

Group type: EXPERIMENTAL
Intervention: Exercise pulmonary hypertension (ePH) group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Post-capillary pulmonary hypertension (postC PH) group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pre-capillary pulmonary hypertension (preC PH) group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Normal hemodynamics group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ePH and PH groups
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ePH, preC-PH and postC-PH groups
Number of subjects: 40
Study: 35568709

Group type: EXPERIMENTAL
Intervention: Variational autoencoder (VAE) with two latent variables
Number of subjects: 13580
Study: 35568815

Group type: EXPERIMENTAL
Intervention: Anxiolytic treatments
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Increased use of anxiolytics and SSRIs
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Anxiety-like behavior
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Anxiety as a concern
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Medication logs
Number of subjects: 1380
Study: 35568881

Group type: EXPERIMENTAL
Intervention: Pirfenidone treatment
Number of subjects: 66
Study: 35568903

Group type: EXPERIMENTAL
Intervention: Individual-level academic detailing (AD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: AD plus the team-based Learn. Engage. Act. (LEAP) quality improvement (QI) learning program
Number of subjects: 36